FDA clampdown driving Indian compliance investment; ICRA
Indian drugmakers will increase investment in GMP compliance to avoid becoming the next company hit by the FDA, a credit rating agency said.
News & Analysis on the Clinical Development and Manufacture of Large Molecule Drugs